Loading...
Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
BACKGROUND: PARP inhibitors (PARPi) benefit only a fraction of breast cancer patients with BRCA mutations, and their efficacy is even more limited in triple-negative breast cancer (TNBC) due to clinical primary and acquired resistance. Here, we found that the efficacy of the PARPi olaparib in TNBC c...
Na minha lista:
| Udgivet i: | J Exp Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8028839/ https://ncbi.nlm.nih.gov/pubmed/33832512 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-021-01930-w |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|